NCT04851119 2026-02-24Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsChildren's Oncology GroupPhase 1/2 Recruiting147 enrolled
NCT00939770 2020-06-09Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaChildren's Oncology GroupPhase 1/2 Completed122 enrolled 24 charts 2 FDA